Redirection of drug metabolism using antisense technology

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 3, 2001, Pages 249-257

  Arora, V ^a   Iversen, P L ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

Antisense oligonucleotide; Cytochrome P450; Drug metabolism; Metabolic redirection; Phosphorodiamidate morpholino oligonucleotide

Indexed keywords

AMPRENAVIR; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BROMPERIDOL; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 3A4; DICLOFENAC; EFAVIRENZ; ERYTHROMYCIN; INDINAVIR; MIRTAZAPINE; NELFINAVIR; NEUROLEPTIC AGENT; NORTRIPTYLINE; PARACETAMOL; PHENACETIN; QUETIAPINE; RAPAMYCIN; RIFABUTIN; RISPERIDONE; RUPINTRIVIR; SALICYLIC ACID; SAQUINAVIR; TRAZODONE; TROLEANDOMYCIN; UNINDEXED DRUG;

ANIMAL MODEL; ARTICLE; CATALYSIS; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FIRST PASS EFFECT; HUMAN; METABOLISM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; TECHNOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; LIVER; MICE; MICE, KNOCKOUT; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; MORPHOLINES; OLIGONUCLEOTIDES, ANTISENSE; SEQUENCE ALIGNMENT; THIONUCLEOTIDES;

ANIMALIA;

EID: 0034933539     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta
2. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
3. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test
4. Characterization of inter- and intra-intestinal differences in human CYP3A-dependent metabolism
5. Characterization of human small intestinal cytochromes P-450
6. Cytochrome P450 and other determinants of pharmacokinetics, toxicity and efficacy in humans
7. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism
8. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
9. Association of the CYP3A4 genotype with treatment-related leukemia
10. Expression of CYP3A in the human liver - Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
11. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone and growth hormone in cultured hepatocytes
12. Biotransformation of xenobiotics
13. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes
14. Interaction of citrus juices with felodipine an nifedipine
15. 7,8-Benzoflavone stimulates the metabolic activation of aflatoxin B1 to mutagens by human liver
16. Identification and characterization of genes associated with human hepatocellular carcinogenesis
17. Pretranslational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis
18. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2 and CYP3A4 in human hepatocytes in primary culture
19. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
20. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
21. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2
22. Cytochrome P450-null mice
23. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
24. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor
25. Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast
26. Role of CYP2E1 in the hepatotoxicity of acetaminophen
27. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression
28. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice
29. Cytochrome P450 3A4: Regulation and role in drug metabolism
30. In vitro and in vivo drug interactions involving human CYP3A
31. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
32. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism
33. Cytochrome P450 and its interactions with the heme biosynthetic pathway
34. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis
35. Inhibition of cyclic AMP-triggered aromatase gene expression in human choriocarcinoma cells by antisense oligodeoxynucleotide
36. PAAn-1b and PAAn-E: Two phosphorothioate antisense oligodeoxynucleotides inhibit human aromatase gene expression
37. Cytochrome P450 2C is an EDHF synthase in coronary arteries
38. 2+ changes and dilation in isolated resistance arteries
39. In vivo modulation of the rat cytochrome P450 1A1 by double-stranded phosphorothioate oligodeoxynucleotides
40. Cholesteryl-conjugated phosphorothioate oligodeoxy-nucleotides modulate CYP2B1 expression in vivo
41. Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo
42. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections
43. In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugs
44. Transdermal delivery of antisense compounds
45. Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo
46. Inhibition of cytochrome P450 1A1 by antisense phosphorothioate oligonucleotide in Hepa lclc7 cells
47. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries
48. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus-mediated antisense targeting
49. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man
50. Reaction between metabolically activated acetaminophen and phosphorothioate oligonucleotides
51. 1-adrenergic receptor antagonists
52. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment
53. Antisense properties of morpholino oligomers
54. Resistance of Morpholino phosphorodiamidate oligomers to enzymatic degradation
55. Morpholino antisense oligomers: The case for an RNase H-independent structural type
56. Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA
57. Evaluation of antisense mechanisms of action
58. Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivo
59. c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity
60. Treatment of C57BL/6J-cpk/cpk mice with c-myc antisense oligomer slows cystic disease and modulates protein expression in the kidney
61. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates
62. Pharmacology of a non-ionic morpholino oligomer directed against the rat CYP3A2 mRNA
63. A non-ionic morpholino oligomer against human CYP3A4 mRNA inhibits expression in primary human hepatocytes
64. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs